Estrella Immunopharma Inc
For the period ended Jun 30, 2024. Filed Sep 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 27, 2024
ESLA$0.51+36.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| For the Year Ended | For the Year Ended | |
|---|---|---|
| June 30, | June 30, | |
| 2024 | 2023 | |
| Operating expenses | ||
| Research and development | $4,108,925 | $10,451,212 |
| General and administrative | 3,201,173 | 663,190 |
| Total operating expenses | 7,310,098 | 11,114,402 |
| Loss from Operations | (7,310,098) | (11,114,402) |
| Loss before income taxes | (7,310,098) | (11,114,402) |
| Income taxes provision | (1,625) | - |
| Net loss | $(7,311,723) | $(11,114,402) |
| Net loss applicable to common stock per share, basic and diluted | $(0.27) | $(36.35) |
| Weighted average common stock outstanding, basic and diluted* | 27,103,964 | 305,748 |
| * | Giving retroactive effect to reverse recapitalization effected on September 29, 2023 to reflect exchange ratio of approximately 0.2407 as described in Note 3 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.